Location of Repository

Molecular targets for chemoprevention: role in choosing and developing new agents

By William P. Steward


This is the author's final draft of the paper published as European Journal of Cancer Supplements, 2007, 5(5), pp.388-390. The final published version is available on Science Direct, doi:10.1016/S1359-6349(07)70071-X.Introduction: The field of cancer chemoprevention has developed considerably over the past two decades with several large randomised trials having been undertaken. Some of these have been positive and have included a demonstration of the efficacy of tamoxifen to reduce the risk of breast cancer and finasteride to have an impact on prostate cancer incidence. Unfortunately several trials have been negative and some have even produced results suggesting a deleterious effect of the agent under investigation. Chemoprevention trials are, of necessity, usually very large and extremely costly. To date, one of the main methods for choosing agents to investigate in trials has been retrospective population-based analysis of an apparent association between ingestion of the agent and a reduced incidence of cancer. Unfortunately such analyses are often flawed by many sources of bias. In addition, adverse effects of exposure to such agents over a protracted period have not been anticipated. Successful chemoprevention requires an agent which has a significant impact on cancer risk but is also extremely safe and well tolerated. With the increasing understanding of molecular mechanisms leading to carcinogenesis, it is imperative that cancer preventive agents are developed more rationally and are targeted towards these mechanisms – both to increase efficacy and also to reduce the potential for toxicity. This article will highlight some of the more promising potential targets which can be used to choose and design drugs for testing as chemopreventive agents. The identification of targets could also enable the development of biomarkers to test efficacy during early clinical development

Publisher: Elsevier
Year: 2007
DOI identifier: 10.1016/S1359-6349(07)70071-X.
OAI identifier: oai:lra.le.ac.uk:2381/2692

Suggested articles



  1. (1994). Cancer Prevention Study Group. The Alpha-Tocopheral. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. doi
  2. (2002). Cycling to cancer with cyclin D1. Cancer Biol Ther doi
  3. (1987). Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science doi
  4. (1998). Inhibition of the c-jun N-terminal kinase (JNK) signalling pathway by curcumin. Oncogene doi
  5. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. doi
  6. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet doi
  7. (2003). Targeting cycloocygenase-2 in human neoplasia: rationale and promise. Cancer Cell
  8. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Revs Cancer doi
  9. (2003). The influence of finasteride on the development of prostate cancer.
  10. (2004). The STATs of cancer – new molecular targets come of age. Nature Revs Cancer doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.